Verastem's VS-7375 Shows 93% CA19-9 Drops, Anti-Tumor Activity in mPDAC
VSTM sits 15% above its 52-week low of $3.55.
Summary
Verastem announced compelling preliminary clinical data for its KRAS G12D inhibitor, VS-7375, in metastatic pancreatic ductal adenocarcinoma (mPDAC). The data showed anti-tumor activity at 400–900 mg QD and a significant 93% reduction in CA19-9 levels in heavily pretreated mPDAC patients. This positive early-stage data, also detailed in an 8-K filed today, is crucial for validating the drug's potential in a difficult-to-treat cancer. Dose escalation is ongoing, and combination cohorts are cleared for further enrollment, indicating continued development for this key pipeline asset.
At the time of this announcement, VSTM was trading at $4.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $369.9M. The 52-week trading range was $3.55 to $11.25. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.